|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A systematic review is performed with the aim of cataloguing predicted pathogenic PALB2 variants in breast, ovary and pancreas cancers.
|
31619740 |
2020 |
|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Inherited pathogenic variants in PALB2 are associated with increased risk of breast and pancreatic cancer.
|
31636395 |
2020 |
|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations in PALB2 have been associated with a predisposition to breast and pancreatic cancers.
|
30255452 |
2019 |
|
Malignant neoplasm of pancreas
|
0.500 |
Biomarker
|
disease |
BEFREE |
Since its identification as a BRCA2 interacting partner, PALB2 has emerged as a pivotal tumor suppressor protein associated to hereditary cancer susceptibility to breast and pancreatic cancers.
|
28858227 |
2017 |
|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Results Thirty-three (3.9%; 95% CI, 3.0% to 5.8%) of 854 patients with pancreatic cancer had a deleterious germline mutation, 31 (3.5%) of which affected known familial pancreatic cancer susceptibility genes: BRCA2 (12 patients), ATM (10 patients), BRCA1 (3 patients), PALB2 (2 patients), MLH1 (2 patients), CDKN2A (1 patient), and TP53 (1 patient).
|
28767289 |
2017 |
|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PALB2 (Partner and Localizer of BRCA2) was identified as a moderate-risk gene in breast and pancreatic cancers.
|
26411315 |
2016 |
|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The PALB2 509_510delGA and 172_175delTTGT mutations combined were seen in 2 (0.52%) unselected cases of PaCa and in 8 (0.20%) of 4,000 controls (OR: 2.61, p = 0.49).
|
27038244 |
2016 |
|
Malignant neoplasm of pancreas
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results indicate that hereditary PALB2 mutation represents clinically considerable genetic factor increasing PDAC susceptibility in our population and that analysis of PALB2 should be considered not only in PDAC patients with familial history of breast or pancreatic cancers but also in younger PDAC patients without family cancer history.
|
27106063 |
2016 |
|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations in PALB2 have been associated with a predisposition to breast and pancreatic cancers.
|
27757719 |
2016 |
|
Malignant neoplasm of pancreas
|
0.500 |
Biomarker
|
disease |
CTD_human |
Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer.
|
26098869 |
2015 |
|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the PALB2 gene are responsible for a small but significant percentage of cancer risks in familial breast and pancreatic cancer families.
|
25542327 |
2015 |
|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The proband carrier of c.3047T>C (p.F1016S) showed two breast cancer cases, two ovarian cancer cases and one pancreatic cancer in mother's family. c.3047T>C (p.F1016S) and c.*146A>G should be considered PALB2 UVs even though the genotype-phenotype correlation for these variants remains still unclear.
|
25666743 |
2015 |
|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Biallelic mutations in PALB2 cause FA (Fanconi's anaemia) subtype FA-N, a devastating inherited disorder marked by developmental abnormalities, bone marrow failure and childhood cancer susceptibility, whereas monoallelic mutations predispose to breast, ovarian and pancreatic cancer.
|
24870022 |
2014 |
|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The goal of this study was to determine the prevalence of PALB2 mutations in a population of BRCA1/BRCA2 negative breast cancer patients selected from either a personal or family history of pancreatic cancer.
|
23935836 |
2013 |
|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However, a subset of pancreatic cancer is attributable to known inherited cancer predisposition syndromes, including several hereditary breast cancer genes (BRCA1, BRCA2, and PALB2), CDKN2A, hereditary pancreatitis, hereditary nonpolyposis colorectal cancer, and Peutz-Jeghers syndrome.
|
22846737 |
2013 |
|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germ-line mutations in PALB2 lead to a familial predisposition to breast and pancreatic cancer or to Fanconi Anemia subtype N. PALB2 performs its tumor suppressor role, at least in part, by supporting homologous recombination-type double strand break repair (HR-DSBR) through physical interactions with BRCA1, BRCA2, and RAD51.
|
23657012 |
2013 |
|
Malignant neoplasm of pancreas
|
0.500 |
Biomarker
|
disease |
BEFREE |
Therefore, PALB2 does not have a major causal role in familial clustering of PC and BC in non-BRCA1/2 families in the Dutch population.
|
22166947 |
2012 |
|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy.
|
21989927 |
2012 |
|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These consist of high penetrance genes including BRCA2 or PALB2, to more common genetic variation associated with a modest increase risk of pancreatic cancer such as genetic variation at the ABO blood group locus.
|
22162228 |
2012 |
|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PALB2 mutation analysis was performed in 110 non-BRCA1/2 cancer patients: (a) 53 ovarian cancer patients from female breast-and/or ovarian cancer families; (b) 45 breast cancer patients with a first or second degree relative with pancreatic cancer; and (c) 12 male breast cancer patients from female breast cancer families.
|
20582465 |
2011 |
|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Routine screening of breast-pancreas cancer families for the presence of PALB2 mutations appears to be low yield.
|
21415078 |
2011 |
|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The prevalence rate of PALB2 mutations in a non-BRCA1/2 breast cancer population specifically selected for a family history of pancreatic cancer does not appear to be significantly increased compared to that observed in other breast cancer populations studied thus far.
|
21365267 |
2011 |
|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This work suggests that inactivation of the PALB2 gene is a determinant of response to DNA damage in pancreatic cancer and a new target for personalizing cancer treatment.
|
21135251 |
2011 |
|
Malignant neoplasm of pancreas
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In addition, no significant associations were observed between 11 PALB2 tagging SNPs and melanoma risk in 23 melanoma-prone families with CDKN2A mutations or the subset of 11 families with PC or PC-related CDKN2A mutations.
|
21614589 |
2011 |
|
Malignant neoplasm of pancreas
|
0.500 |
Biomarker
|
disease |
BEFREE |
PALB2 heterozygotes were 4-fold more likely to have a male relative with breast cancer (P = 0.0003), 6-fold more likely to have a relative with pancreatic cancer (P = 0.002), and 1.3-fold more likely to have a relative with ovarian cancer (P = 0.18).
|
21285249 |
2011 |